Sesen Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sesen Bio, Inc.
New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.
Novartis is trying its luck with capmatinib on the accelerated assessment front at the European Medicines Agency. Gilead and Astellas/Seagen have secured fast-track review for their respective potential new products while Sesen Bio and Amryt Pharma are dealing with rejection.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Eleven Biotherapeutics, Inc.
- Viventia Bio Inc.